Trevi Therapeutics Files Q3 2024 10-Q
Ticker: TRVI · Form: 10-Q · Filed: Nov 6, 2024 · CIK: 1563880
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals, stock-plans
TL;DR
Trevi Therapeutics filed its Q3 2024 10-Q. Financials and stock activity detailed.
AI Summary
Trevi Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates. Key financial figures and activities from the period are presented, including information related to stock incentive plans and offerings.
Why It Matters
This filing provides investors with an update on Trevi Therapeutics' financial health and operational progress for the third quarter of 2024, crucial for assessing the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Trevi Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024-09-30 — Reporting Period End Date (The 10-Q covers financial activities up to this date.)
- 2024-11-06 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Trevi Therapeutics, Inc. (company) — Filer of the 10-Q
- 2024-09-30 (date) — End of the reporting period
- 2024-11-06 (date) — Filing date
- New Haven, CT (location) — Company's business and mailing address
- New Enterprise Associates 16 Limited Partnership (company) — Investor in common stock and warrants
FAQ
What is the primary business of Trevi Therapeutics, Inc.?
Trevi Therapeutics, Inc. is primarily involved in the Pharmaceutical Preparations industry, as indicated by its SIC code [2834].
What is the fiscal year end for Trevi Therapeutics?
The fiscal year end for Trevi Therapeutics is December 31st.
When was the September Two Thousand Twenty-Two Offering mentioned in the filing?
The September Two Thousand Twenty-Two Offering, specifically the Underwriting Agreement, is dated September 27, 2022.
What specific stock plans are mentioned for the period January 1, 2024, to September 30, 2024?
The filing mentions the Two Thousand Twelve Stock Incentive Plan and the Two Thousand Nineteen Employee Stock Purchase Plan for the period January 1, 2024, to September 30, 2024.
Who is listed as an investor in common stock and accompanying warrants via private placement?
New Enterprise Associates 16 Limited Partnership is listed as an investor in common stock and accompanying common stock warrants via private placement during the period January 1, 2024, to September 30, 2024.
Filing Stats: 4,449 words · 18 min read · ~15 pages · Grade level 17.8 · Accepted 2024-11-06 16:20:16
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share TRVI The Nasdaq
Filing Documents
- trvi-20240930.htm (10-Q) — 2252KB
- trvi-ex10_2.htm (EX-10.2) — 119KB
- trvi-ex10_3.htm (EX-10.3) — 39KB
- trvi-ex31_1.htm (EX-31.1) — 15KB
- trvi-ex31_2.htm (EX-31.2) — 15KB
- trvi-ex32_1.htm (EX-32.1) — 10KB
- trvi-ex32_2.htm (EX-32.2) — 10KB
- img65733204_0.jpg (GRAPHIC) — 11KB
- img66656725_0.jpg (GRAPHIC) — 39KB
- 0000950170-24-122355.txt ( ) — 8850KB
- trvi-20240930.xsd (EX-101.SCH) — 1134KB
- trvi-20240930_htm.xml (XML) — 1479KB
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 28 Item 4.
Controls and Procedures
Controls and Procedures 28 PART II. OTHER INFORMATION Item 1.
Legal Proceedings
Legal Proceedings 28 Item 1A.
Risk Factors
Risk Factors 28 Item 5. Other Information 70 Item 6. Exhibits 70
—FINANCI AL INFORMATION
PART I—FINANCI AL INFORMATION
Condensed Consolidated Financi al Statements
Item 1. Condensed Consolidated Financi al Statements. Trevi Therapeutics, Inc. Condensed Consolida ted Balance Sheets (Amounts in thousands, except share and per share amounts) September 30, 2024 December 31, 2023 Assets Unaudited Current assets: Cash and cash equivalents $ 16,052 $ 32,397 Marketable securities 49,441 50,574 Prepaid expenses 1,176 3,621 Other current assets 667 955 Total current assets 67,336 87,547 Operating lease right-of-use assets 973 1,137 Finance lease right-of-use assets 169 206 Property, equipment and leasehold improvements, net 174 216 Other non-current assets 256 297 Total assets $ 68,908 $ 89,403 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 1,614 $ 1,809 Accrued expenses 7,212 3,709 Operating lease liabilities 235 184 Finance lease liabilities 62 122 Total current liabilities 9,123 5,824 Operating lease liabilities 816 1,001 Finance lease liabilities — 31 Total liabilities 9,939 6,856 Commitments and contingencies (Note 12) Stockholders' equity: Preferred stock: $ 0.001 par value; 5,000,000 shares authorized at September 30, 2024 and December 31, 2023; no shares issued or outstanding at September 30, 2024 and December 31, 2023. — — Common stock: $ 0.001 par value; 200,000,000 shares authorized at September 30, 2024 and December 31, 2023; and 75,454,375 and 68,283,699 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively. 75 68 Additional paid-in capital 334,385 321,642 Accumulated other comprehensive income (loss) 139 ( 29 ) Accumulated deficit ( 275,630 ) ( 239,134 ) Total stockholders' equity 58,969 82,547 Total liabilities and stockholders' equity $ 68,908 $ 89,403 The accompanying notes are an integral part of these condensed consolidated financial statements. 1 Trevi The